{"url_path":"/sec/sgp/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1778922/0001778922-26-000035-index.html","accession_number":"0001778922-26-000035","cik":"0001778922","ticker":"SGP","issuer_name":"SpyGlass Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1778922/0001778922-26-000035-index.html","primary_entity_key":"0001778922","primary_entity_name":"SpyGlass Pharma, Inc."},"word_count":322,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds\n\nUnregistered Sales of Equity Securities\n\nOn February 5, 2026, we granted to certain of our service providers stock options to purchase an aggregate of 1,312,044 shares of our common stock under the 2026 Plan at a weighted-average exercise price of $16.00 per share.\n\nIn January 2026, we issued and sold to our employees an aggregate of 99,719 shares of common stock upon the exercise of stock options issued under the 2019 Plan at exercise prices ranging from $0.38 to $2.18 per share, for an aggregate exercise price of $41.3 thousand.\n\nThese issuances were deemed to be exempt from registration under the Securities Act pursuant to Rule 701 promulgated under the Securities Act.\n\nUse of Proceeds\n\nOn February 9, 2026, we completed our IPO, in which we issued and sold 10,781,250 shares of our common stock, at a price to the public of $16.00 per share. The net proceeds to the Company from the IPO were approximately $156.5 million, after deducting underwriting fees and offering costs. All of the shares of common stock issued and sold in our IPO were registered under the Securities Act, pursuant to a registration statement on Form S-1 (File No. 333-292779), which was declared effective by the SEC on January 30, 2025. Jefferies LLC, Leerink Partners LLC, Citigroup Global Markets Inc. and Stifel, Nicolaus & Company, Incorporated acted as representatives of the several underwriters of the IPO. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates.\n\nThere has been no material change in the intended use of proceeds from our IPO as described in our prospectus dated February 5, 2026 (File No. 333-292779), as filed with the SEC on February 6, 2026 pursuant to Rule 424(b)(4) under the Securities Act."}